Document is current
Any future updates will be listed below
-
Authors
Laganà, Alessandro https://orcid.org/0009-0005-9432-224X
Scalzulli, Emilia
Carmosino, Ida
Bisegna, Maria L.
Martelli, Maurizio
Breccia, Massimo https://orcid.org/0000-0003-1163-6162
- License Information
-
More Information
Article History
Received: 10 September 2024
Accepted: 6 December 2024
First Online: 17 January 2025
Declarations
:
: Massimo Breccia received honoraria from Novartis, Incyte, Pfizer, Abbvie, GSK. Massimo Breccia is an Editorial Board member of Oncology and Therapy. Massimo Breccia was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Maurizio Martelli received honoraria from Roche, Gilead Sciences, Novartis, Abbvie, Incyte, BeiGene, Takeda, and Bristol Myers Squibb/Celgene. Alessandro Laganà, Emilia Scalzulli, Ida Carmosino, and Maria Laura Bisegna declare no conflict of interest.
: This study was a non-interventional, retrospective analysis involving de-identified claims data. All patients signed the informed consent to treatment and to use of their clinical data for scientific purposes. Institutional review board (IRB) approval was not required for this retrospective study as, according to the rules of “Sapienza” University of Rome-Policlinico Umberto I, it is not needed if studies utilize data where formal consent was obtained from patients.
